Loading people...
Alexis Yongmei Ji is a Partner at Illumina Ventures based in the San Francisco Bay Area. Before joining the firm at its 2016 founding, she served as a Principal at WuXi Healthcare Ventures and held investment roles at the Roche Venture Fund and Arch Venture Partners. Her venture capital career is preceded by corporate strategy and research scientist positions at Merck, Roche, and Life Technologies. She holds a doctorate in molecular genetics from Washington University in St. Louis and a Master of Business Administration from the University of Chicago Booth School of Business. Ji directs capital from Illumina's $325 million second fund into early-stage biotechnology startups, serving on the board of Alamar Biosciences following its $100 million Series C round in 2024. Her current investment focus centers on genomics-enabled precision medicine, clinical diagnostics, and life science tools.
Alexis Yongmei Ji serves as a distinguished Partner at Illumina Ventures, a leading venture capital firm dedicated to investing in early-stage life science companies. In her crucial role, Alexis is instrumental in identifying, evaluating, and supporting innovative startups that are poised to revolutionize healthcare and biotechnology. Her work at Illumina Ventures aligns with the firm's mission to back entrepreneurs who are leveraging cutting-edge science and technology to create significant impact.
Alexis's investment focus areas are broad yet strategically targeted, reflecting the dynamic landscape of modern medicine. She actively seeks out companies developing advancements in genomics, precision medicine, diagnostics, and novel therapeutics. Her expertise extends to biotechnology tools and platforms, digital health solutions, and other disruptive technologies that can enhance human health and well-being. She is particularly interested in ventures that can benefit from or contribute to the broader Illumina ecosystem, fostering synergistic growth and innovation.
Before joining Illumina Ventures, Alexis Yongmei Ji cultivated a robust career background that equipped her with a unique blend of scientific acumen and strategic investment insight. While specific details of her prior roles are not publicly detailed, her trajectory likely involved significant experience in scientific research, clinical development, or prior venture capital/private equity roles within the life sciences. This foundation allows her to deeply understand the complex scientific challenges and market opportunities faced by early-stage companies. Her analytical rigor and forward-thinking approach are invaluable in assessing the long-term potential of emerging technologies and business models.
As a Partner, Alexis contributes significantly to Illumina Ventures' impressive portfolio, helping to shape the future of healthcare. While specific individual investments are often part of a broader team effort, her contributions are vital in sourcing promising deals, conducting thorough due diligence, and providing strategic guidance to portfolio companies. She is known for her collaborative approach, working closely with founders and management teams to navigate the complexities of product development, regulatory pathways, and market entry. Her commitment to fostering innovation ensures that Illumina Ventures continues to be a catalyst for progress in the life science sector. Alexis Yongmei Ji is a key figure in driving the firm's success and advancing the next generation of healthcare breakthroughs.
Alexis Yongmei Ji is a Partner at Illumina Ventures, a venture capital firm specializing in early-stage life science and healthcare investments. She plays a key role in identifying and supporting innovative companies.
Alexis Yongmei Ji invests in early-stage companies across the life science and healthcare sectors. Her focus areas include genomics, precision medicine, diagnostics, novel therapeutics, biotechnology tools, and digital health solutions.
Alexis Yongmei Ji works as a Partner at Illumina Ventures, a leading venture capital firm dedicated to advancing innovation in life sciences.
